nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CBR1—Doxorubicin—hematologic cancer	0.386	1	CbGbCtD
Lubiprostone—CLCN2—gonad—hematologic cancer	0.0169	0.173	CbGeAlD
Lubiprostone—CLCN2—blood—hematologic cancer	0.0147	0.151	CbGeAlD
Lubiprostone—CLCN2—lung—hematologic cancer	0.0129	0.132	CbGeAlD
Lubiprostone—CLCN2—testis—hematologic cancer	0.0122	0.125	CbGeAlD
Lubiprostone—CLCN2—lymph node—hematologic cancer	0.00883	0.0905	CbGeAlD
Lubiprostone—Misoprostol—PTGER4—hematologic cancer	0.00758	0.724	CrCbGaD
Lubiprostone—CBR1—gonad—hematologic cancer	0.00677	0.0695	CbGeAlD
Lubiprostone—CBR1—blood—hematologic cancer	0.0059	0.0605	CbGeAlD
Lubiprostone—CBR1—bone marrow—hematologic cancer	0.00571	0.0586	CbGeAlD
Lubiprostone—CBR1—lung—hematologic cancer	0.00517	0.0531	CbGeAlD
Lubiprostone—CLCN2—Ion channel transport—FXYD6—hematologic cancer	0.0051	0.076	CbGpPWpGaD
Lubiprostone—CBR1—testis—hematologic cancer	0.00488	0.0501	CbGeAlD
Lubiprostone—CLCN2—Stimuli-sensing channels—SGK1—hematologic cancer	0.00483	0.072	CbGpPWpGaD
Lubiprostone—CLCN2—Ion channel transport—ATP1B1—hematologic cancer	0.00363	0.0542	CbGpPWpGaD
Lubiprostone—CBR1—lymph node—hematologic cancer	0.00354	0.0363	CbGeAlD
Lubiprostone—CLCN2—Ion channel transport—ATP4A—hematologic cancer	0.00315	0.047	CbGpPWpGaD
Lubiprostone—CLCN2—Ion channel transport—SGK1—hematologic cancer	0.00315	0.047	CbGpPWpGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—ALOX5—hematologic cancer	0.00244	0.0363	CbGpPWpGaD
Lubiprostone—Dinoprostone—PTGER4—hematologic cancer	0.00213	0.203	CrCbGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—AQP9—hematologic cancer	0.00191	0.0285	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—FXYD6—hematologic cancer	0.00178	0.0265	CbGpPWpGaD
Lubiprostone—CBR1—Vincristine—Vinorelbine—hematologic cancer	0.00172	0.201	CbGdCrCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—S100A10—hematologic cancer	0.00145	0.0216	CbGpPWpGaD
Lubiprostone—CBR1—Vincristine—Vinblastine—hematologic cancer	0.00138	0.16	CbGdCrCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	0.00135	0.0201	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	0.00127	0.0189	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	0.0012	0.0179	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—TXN—hematologic cancer	0.00116	0.0173	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—ABCC3—hematologic cancer	0.00116	0.0173	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SGK1—hematologic cancer	0.0011	0.0164	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ANXA2—hematologic cancer	0.0011	0.0164	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ATP4A—hematologic cancer	0.0011	0.0164	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—UGT1A1—hematologic cancer	0.00109	0.0162	CbGpPWpGaD
Lubiprostone—CBR1—Azacitidine—Pentostatin—hematologic cancer	0.00105	0.122	CbGdCrCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	0.000988	0.0147	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PHYH—hematologic cancer	0.00094	0.014	CbGpPWpGaD
Lubiprostone—CBR1—Azacitidine—Clofarabine—hematologic cancer	0.000937	0.109	CbGdCrCtD
Lubiprostone—CBR1—Azacitidine—Nelarabine—hematologic cancer	0.000881	0.103	CbGdCrCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ABCC3—hematologic cancer	0.000867	0.0129	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—SMPD3—hematologic cancer	0.00086	0.0128	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	0.000793	0.0118	CbGpPWpGaD
Lubiprostone—Dinoprostone—SLC22A1—hematologic cancer	0.000755	0.0722	CrCbGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—NUP98—hematologic cancer	0.000748	0.0112	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—NQO1—hematologic cancer	0.000747	0.0111	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ADCY7—hematologic cancer	0.000727	0.0108	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—NUP214—hematologic cancer	0.000721	0.0108	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ABCG2—hematologic cancer	0.000707	0.0105	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—HSP90AA1—hematologic cancer	0.000702	0.0105	CbGpPWpGaD
Lubiprostone—CBR1—Azacitidine—Fludarabine—hematologic cancer	0.000687	0.0801	CbGdCrCtD
Lubiprostone—CBR1—Azacitidine—Gemcitabine—hematologic cancer	0.000649	0.0756	CbGdCrCtD
Lubiprostone—CBR1—Azacitidine—Cytarabine—hematologic cancer	0.000649	0.0756	CbGdCrCtD
Lubiprostone—CBR1—Azacitidine—Cladribine—hematologic cancer	0.000633	0.0737	CbGdCrCtD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—TFRC—hematologic cancer	0.00063	0.00939	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTP1—hematologic cancer	0.000623	0.00929	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—GBA—hematologic cancer	0.000606	0.00903	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—HGF—hematologic cancer	0.000573	0.00854	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—GSTM1—hematologic cancer	0.000573	0.00854	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—CYCS—hematologic cancer	0.000529	0.00788	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—FHL2—hematologic cancer	0.000494	0.00736	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—PDGFB—hematologic cancer	0.000493	0.00734	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ABCB1—hematologic cancer	0.000441	0.00658	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	0.000432	0.00644	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GMPS—hematologic cancer	0.000419	0.00624	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PHYH—hematologic cancer	0.000419	0.00624	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—FTCD—hematologic cancer	0.000419	0.00624	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	0.000415	0.00618	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	0.000395	0.00589	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	0.00039	0.00582	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SMPD3—hematologic cancer	0.000383	0.00571	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	0.000382	0.0057	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	0.000357	0.00532	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	0.000348	0.00519	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—B3GAT1—hematologic cancer	0.000335	0.00499	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ASNS—hematologic cancer	0.000335	0.00499	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—DCK—hematologic cancer	0.000335	0.00499	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	0.000327	0.00488	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—HDC—hematologic cancer	0.000317	0.00473	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	0.000296	0.00441	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	0.000295	0.00439	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CDA—hematologic cancer	0.00029	0.00433	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PC—hematologic cancer	0.000279	0.00417	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—ALB—hematologic cancer	0.000276	0.00411	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GBA—hematologic cancer	0.00027	0.00402	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SLC35B2—hematologic cancer	0.00027	0.00402	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—MTAP—hematologic cancer	0.000247	0.00368	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—TGFB1—hematologic cancer	0.000233	0.00348	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—FHL2—hematologic cancer	0.00022	0.00328	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—AGRN—hematologic cancer	0.000216	0.00322	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—IDH2—hematologic cancer	0.000205	0.00305	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—HMMR—hematologic cancer	0.000205	0.00305	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	0.000193	0.00287	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ARNTL—hematologic cancer	0.000192	0.00287	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CA9—hematologic cancer	0.000187	0.00279	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ACP5—hematologic cancer	0.000187	0.00279	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—NCOR2—hematologic cancer	0.000185	0.00275	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—IDH1—hematologic cancer	0.000176	0.00262	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GSTO1—hematologic cancer	0.000174	0.00259	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ABCC3—hematologic cancer	0.000174	0.00259	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—TXN—hematologic cancer	0.000174	0.00259	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SPHK1—hematologic cancer	0.00017	0.00254	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—UGT1A1—hematologic cancer	0.000163	0.00244	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CRABP1—hematologic cancer	0.000159	0.00237	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SLC22A1—hematologic cancer	0.000159	0.00237	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ALOX5—hematologic cancer	0.000155	0.00231	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—NUP98—hematologic cancer	0.00015	0.00224	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ADCY7—hematologic cancer	0.000146	0.00217	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—NCOA3—hematologic cancer	0.000146	0.00217	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—NUP214—hematologic cancer	0.000145	0.00216	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	0.000143	0.00213	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—MTR—hematologic cancer	0.000142	0.00211	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ABCG2—hematologic cancer	0.000142	0.00211	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—ENO2—hematologic cancer	0.000139	0.00207	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GSTT1—hematologic cancer	0.000135	0.00201	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	0.000133	0.00198	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SDC1—hematologic cancer	0.000132	0.00196	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	0.000126	0.00188	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	0.000124	0.00185	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	0.000119	0.00177	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CD44—hematologic cancer	0.000112	0.00167	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—NQO1—hematologic cancer	0.000112	0.00167	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	0.00011	0.00164	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CYCS—hematologic cancer	0.000106	0.00158	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—HSP90AA1—hematologic cancer	0.000105	0.00157	CbGpPWpGaD
Lubiprostone—Anorexia—Dexamethasone—hematologic cancer	0.000105	0.000245	CcSEcCtD
Lubiprostone—Anorexia—Betamethasone—hematologic cancer	0.000105	0.000245	CcSEcCtD
Lubiprostone—Asthenia—Cisplatin—hematologic cancer	0.000105	0.000244	CcSEcCtD
Lubiprostone—Fatigue—Triamcinolone—hematologic cancer	0.000105	0.000244	CcSEcCtD
Lubiprostone—Rash—Vincristine—hematologic cancer	0.000104	0.000243	CcSEcCtD
Lubiprostone—Dermatitis—Vincristine—hematologic cancer	0.000104	0.000243	CcSEcCtD
Lubiprostone—Oedema peripheral—Epirubicin—hematologic cancer	0.000104	0.000242	CcSEcCtD
Lubiprostone—Pain—Triamcinolone—hematologic cancer	0.000104	0.000242	CcSEcCtD
Lubiprostone—Connective tissue disorder—Epirubicin—hematologic cancer	0.000104	0.000242	CcSEcCtD
Lubiprostone—Headache—Vincristine—hematologic cancer	0.000104	0.000241	CcSEcCtD
Lubiprostone—Loss of consciousness—Prednisone—hematologic cancer	0.000104	0.000241	CcSEcCtD
Lubiprostone—Nausea—Carmustine—hematologic cancer	0.000103	0.00024	CcSEcCtD
Lubiprostone—Vomiting—Mitoxantrone—hematologic cancer	0.000103	0.000238	CcSEcCtD
Lubiprostone—Vomiting—Irinotecan—hematologic cancer	0.000103	0.000238	CcSEcCtD
Lubiprostone—Nausea—Alitretinoin—hematologic cancer	0.000102	0.000237	CcSEcCtD
Lubiprostone—Mediastinal disorder—Methotrexate—hematologic cancer	0.000102	0.000237	CcSEcCtD
Lubiprostone—Rash—Mitoxantrone—hematologic cancer	0.000102	0.000236	CcSEcCtD
Lubiprostone—Rash—Irinotecan—hematologic cancer	0.000102	0.000236	CcSEcCtD
Lubiprostone—Dermatitis—Mitoxantrone—hematologic cancer	0.000102	0.000236	CcSEcCtD
Lubiprostone—Dermatitis—Irinotecan—hematologic cancer	0.000102	0.000236	CcSEcCtD
Lubiprostone—Headache—Mitoxantrone—hematologic cancer	0.000101	0.000235	CcSEcCtD
Lubiprostone—Headache—Irinotecan—hematologic cancer	0.000101	0.000235	CcSEcCtD
Lubiprostone—Nausea—Ifosfamide—hematologic cancer	0.000101	0.000235	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Betamethasone—hematologic cancer	0.000101	0.000234	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	0.000101	0.000234	CcSEcCtD
Lubiprostone—Myalgia—Prednisone—hematologic cancer	0.0001	0.000233	CcSEcCtD
Lubiprostone—Feeling abnormal—Triamcinolone—hematologic cancer	0.0001	0.000233	CcSEcCtD
Lubiprostone—Diarrhoea—Cisplatin—hematologic cancer	0.0001	0.000233	CcSEcCtD
Lubiprostone—Anxiety—Prednisone—hematologic cancer	0.0001	0.000232	CcSEcCtD
Lubiprostone—Vomiting—Gemcitabine—hematologic cancer	9.99e-05	0.000232	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	9.97e-05	0.000232	CcSEcCtD
Lubiprostone—Discomfort—Prednisone—hematologic cancer	9.91e-05	0.00023	CcSEcCtD
Lubiprostone—Mental disorder—Methotrexate—hematologic cancer	9.91e-05	0.00023	CcSEcCtD
Lubiprostone—Rash—Gemcitabine—hematologic cancer	9.91e-05	0.00023	CcSEcCtD
Lubiprostone—Dermatitis—Gemcitabine—hematologic cancer	9.9e-05	0.00023	CcSEcCtD
Lubiprostone—Hypersensitivity—Etoposide—hematologic cancer	9.89e-05	0.00023	CcSEcCtD
Lubiprostone—Malnutrition—Methotrexate—hematologic cancer	9.85e-05	0.000229	CcSEcCtD
Lubiprostone—Erythema—Methotrexate—hematologic cancer	9.85e-05	0.000229	CcSEcCtD
Lubiprostone—Headache—Gemcitabine—hematologic cancer	9.85e-05	0.000229	CcSEcCtD
Lubiprostone—Nausea—Vincristine—hematologic cancer	9.84e-05	0.000229	CcSEcCtD
Lubiprostone—Hypersensitivity—Prednisolone—hematologic cancer	9.75e-05	0.000227	CcSEcCtD
Lubiprostone—Dyspepsia—Betamethasone—hematologic cancer	9.72e-05	0.000226	CcSEcCtD
Lubiprostone—Dyspepsia—Dexamethasone—hematologic cancer	9.72e-05	0.000226	CcSEcCtD
Lubiprostone—Oedema peripheral—Doxorubicin—hematologic cancer	9.65e-05	0.000224	CcSEcCtD
Lubiprostone—Dysgeusia—Methotrexate—hematologic cancer	9.65e-05	0.000224	CcSEcCtD
Lubiprostone—Asthenia—Etoposide—hematologic cancer	9.63e-05	0.000224	CcSEcCtD
Lubiprostone—Connective tissue disorder—Doxorubicin—hematologic cancer	9.63e-05	0.000224	CcSEcCtD
Lubiprostone—Oedema—Prednisone—hematologic cancer	9.62e-05	0.000224	CcSEcCtD
Lubiprostone—Decreased appetite—Betamethasone—hematologic cancer	9.6e-05	0.000223	CcSEcCtD
Lubiprostone—Decreased appetite—Dexamethasone—hematologic cancer	9.6e-05	0.000223	CcSEcCtD
Lubiprostone—Nausea—Irinotecan—hematologic cancer	9.58e-05	0.000223	CcSEcCtD
Lubiprostone—Nausea—Mitoxantrone—hematologic cancer	9.58e-05	0.000223	CcSEcCtD
Lubiprostone—Mediastinal disorder—Epirubicin—hematologic cancer	9.54e-05	0.000222	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Betamethasone—hematologic cancer	9.54e-05	0.000222	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Dexamethasone—hematologic cancer	9.54e-05	0.000222	CcSEcCtD
Lubiprostone—Fatigue—Betamethasone—hematologic cancer	9.52e-05	0.000221	CcSEcCtD
Lubiprostone—Fatigue—Dexamethasone—hematologic cancer	9.52e-05	0.000221	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	9.48e-05	0.00141	CbGpPWpGaD
Lubiprostone—Shock—Prednisone—hematologic cancer	9.46e-05	0.00022	CcSEcCtD
Lubiprostone—Pain—Dexamethasone—hematologic cancer	9.45e-05	0.000219	CcSEcCtD
Lubiprostone—Pain—Betamethasone—hematologic cancer	9.45e-05	0.000219	CcSEcCtD
Lubiprostone—Nervous system disorder—Prednisone—hematologic cancer	9.43e-05	0.000219	CcSEcCtD
Lubiprostone—Tachycardia—Prednisone—hematologic cancer	9.39e-05	0.000218	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GSTP1—hematologic cancer	9.35e-05	0.00139	CbGpPWpGaD
Lubiprostone—Skin disorder—Prednisone—hematologic cancer	9.34e-05	0.000217	CcSEcCtD
Lubiprostone—Nausea—Gemcitabine—hematologic cancer	9.34e-05	0.000217	CcSEcCtD
Lubiprostone—Vomiting—Cisplatin—hematologic cancer	9.31e-05	0.000216	CcSEcCtD
Lubiprostone—Hyperhidrosis—Prednisone—hematologic cancer	9.3e-05	0.000216	CcSEcCtD
Lubiprostone—Mental disorder—Epirubicin—hematologic cancer	9.28e-05	0.000216	CcSEcCtD
Lubiprostone—Rash—Cisplatin—hematologic cancer	9.24e-05	0.000215	CcSEcCtD
Lubiprostone—Dermatitis—Cisplatin—hematologic cancer	9.23e-05	0.000214	CcSEcCtD
Lubiprostone—Erythema—Epirubicin—hematologic cancer	9.22e-05	0.000214	CcSEcCtD
Lubiprostone—Malnutrition—Epirubicin—hematologic cancer	9.22e-05	0.000214	CcSEcCtD
Lubiprostone—Diarrhoea—Etoposide—hematologic cancer	9.18e-05	0.000213	CcSEcCtD
Lubiprostone—Anorexia—Prednisone—hematologic cancer	9.17e-05	0.000213	CcSEcCtD
Lubiprostone—Ill-defined disorder—Methotrexate—hematologic cancer	9.14e-05	0.000212	CcSEcCtD
Lubiprostone—Feeling abnormal—Betamethasone—hematologic cancer	9.1e-05	0.000211	CcSEcCtD
Lubiprostone—Feeling abnormal—Dexamethasone—hematologic cancer	9.1e-05	0.000211	CcSEcCtD
Lubiprostone—Flatulence—Epirubicin—hematologic cancer	9.08e-05	0.000211	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	9.04e-05	0.00135	CbGpPWpGaD
Lubiprostone—Gastrointestinal pain—Betamethasone—hematologic cancer	9.03e-05	0.00021	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Dexamethasone—hematologic cancer	9.03e-05	0.00021	CcSEcCtD
Lubiprostone—Dysgeusia—Epirubicin—hematologic cancer	9.03e-05	0.00021	CcSEcCtD
Lubiprostone—Hypersensitivity—Triamcinolone—hematologic cancer	8.97e-05	0.000208	CcSEcCtD
Lubiprostone—Malaise—Methotrexate—hematologic cancer	8.88e-05	0.000206	CcSEcCtD
Lubiprostone—Dizziness—Etoposide—hematologic cancer	8.88e-05	0.000206	CcSEcCtD
Lubiprostone—Muscle spasms—Epirubicin—hematologic cancer	8.86e-05	0.000206	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ABCB1—hematologic cancer	8.85e-05	0.00132	CbGpPWpGaD
Lubiprostone—Mediastinal disorder—Doxorubicin—hematologic cancer	8.83e-05	0.000205	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Prednisone—hematologic cancer	8.76e-05	0.000204	CcSEcCtD
Lubiprostone—Dizziness—Prednisolone—hematologic cancer	8.75e-05	0.000203	CcSEcCtD
Lubiprostone—Asthenia—Triamcinolone—hematologic cancer	8.73e-05	0.000203	CcSEcCtD
Lubiprostone—Abdominal pain—Betamethasone—hematologic cancer	8.73e-05	0.000203	CcSEcCtD
Lubiprostone—Abdominal pain—Dexamethasone—hematologic cancer	8.73e-05	0.000203	CcSEcCtD
Lubiprostone—Nausea—Cisplatin—hematologic cancer	8.7e-05	0.000202	CcSEcCtD
Lubiprostone—Cough—Methotrexate—hematologic cancer	8.6e-05	0.0002	CcSEcCtD
Lubiprostone—CBR1—Metabolism—GSTM1—hematologic cancer	8.59e-05	0.00128	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—NCOR1—hematologic cancer	8.59e-05	0.00128	CbGpPWpGaD
Lubiprostone—Mental disorder—Doxorubicin—hematologic cancer	8.58e-05	0.000199	CcSEcCtD
Lubiprostone—Ill-defined disorder—Epirubicin—hematologic cancer	8.55e-05	0.000199	CcSEcCtD
Lubiprostone—Vomiting—Etoposide—hematologic cancer	8.53e-05	0.000198	CcSEcCtD
Lubiprostone—Erythema—Doxorubicin—hematologic cancer	8.53e-05	0.000198	CcSEcCtD
Lubiprostone—Malnutrition—Doxorubicin—hematologic cancer	8.53e-05	0.000198	CcSEcCtD
Lubiprostone—Dyspepsia—Prednisone—hematologic cancer	8.47e-05	0.000197	CcSEcCtD
Lubiprostone—Rash—Etoposide—hematologic cancer	8.46e-05	0.000197	CcSEcCtD
Lubiprostone—Dermatitis—Etoposide—hematologic cancer	8.45e-05	0.000196	CcSEcCtD
Lubiprostone—Headache—Etoposide—hematologic cancer	8.41e-05	0.000195	CcSEcCtD
Lubiprostone—Flatulence—Doxorubicin—hematologic cancer	8.41e-05	0.000195	CcSEcCtD
Lubiprostone—Chest pain—Methotrexate—hematologic cancer	8.39e-05	0.000195	CcSEcCtD
Lubiprostone—Myalgia—Methotrexate—hematologic cancer	8.39e-05	0.000195	CcSEcCtD
Lubiprostone—Decreased appetite—Prednisone—hematologic cancer	8.36e-05	0.000194	CcSEcCtD
Lubiprostone—Dysgeusia—Doxorubicin—hematologic cancer	8.35e-05	0.000194	CcSEcCtD
Lubiprostone—Rash—Prednisolone—hematologic cancer	8.35e-05	0.000194	CcSEcCtD
Lubiprostone—Dermatitis—Prednisolone—hematologic cancer	8.34e-05	0.000194	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	8.33e-05	0.000194	CcSEcCtD
Lubiprostone—Malaise—Epirubicin—hematologic cancer	8.31e-05	0.000193	CcSEcCtD
Lubiprostone—Fatigue—Prednisone—hematologic cancer	8.29e-05	0.000193	CcSEcCtD
Lubiprostone—Headache—Prednisolone—hematologic cancer	8.29e-05	0.000193	CcSEcCtD
Lubiprostone—Discomfort—Methotrexate—hematologic cancer	8.29e-05	0.000193	CcSEcCtD
Lubiprostone—Syncope—Epirubicin—hematologic cancer	8.27e-05	0.000192	CcSEcCtD
Lubiprostone—Constipation—Prednisone—hematologic cancer	8.23e-05	0.000191	CcSEcCtD
Lubiprostone—Muscle spasms—Doxorubicin—hematologic cancer	8.2e-05	0.000191	CcSEcCtD
Lubiprostone—Palpitations—Epirubicin—hematologic cancer	8.15e-05	0.000189	CcSEcCtD
Lubiprostone—Loss of consciousness—Epirubicin—hematologic cancer	8.1e-05	0.000188	CcSEcCtD
Lubiprostone—Dizziness—Triamcinolone—hematologic cancer	8.05e-05	0.000187	CcSEcCtD
Lubiprostone—Cough—Epirubicin—hematologic cancer	8.04e-05	0.000187	CcSEcCtD
Lubiprostone—Nausea—Etoposide—hematologic cancer	7.97e-05	0.000185	CcSEcCtD
Lubiprostone—Feeling abnormal—Prednisone—hematologic cancer	7.93e-05	0.000184	CcSEcCtD
Lubiprostone—Asthenia—Betamethasone—hematologic cancer	7.93e-05	0.000184	CcSEcCtD
Lubiprostone—Asthenia—Dexamethasone—hematologic cancer	7.93e-05	0.000184	CcSEcCtD
Lubiprostone—Ill-defined disorder—Doxorubicin—hematologic cancer	7.91e-05	0.000184	CcSEcCtD
Lubiprostone—Nervous system disorder—Methotrexate—hematologic cancer	7.88e-05	0.000183	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Prednisone—hematologic cancer	7.87e-05	0.000183	CcSEcCtD
Lubiprostone—Nausea—Prednisolone—hematologic cancer	7.86e-05	0.000183	CcSEcCtD
Lubiprostone—Myalgia—Epirubicin—hematologic cancer	7.85e-05	0.000182	CcSEcCtD
Lubiprostone—Chest pain—Epirubicin—hematologic cancer	7.85e-05	0.000182	CcSEcCtD
Lubiprostone—Anxiety—Epirubicin—hematologic cancer	7.82e-05	0.000182	CcSEcCtD
Lubiprostone—Skin disorder—Methotrexate—hematologic cancer	7.81e-05	0.000181	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	7.79e-05	0.000181	CcSEcCtD
Lubiprostone—Hyperhidrosis—Methotrexate—hematologic cancer	7.77e-05	0.000181	CcSEcCtD
Lubiprostone—Discomfort—Epirubicin—hematologic cancer	7.75e-05	0.00018	CcSEcCtD
Lubiprostone—Vomiting—Triamcinolone—hematologic cancer	7.74e-05	0.00018	CcSEcCtD
Lubiprostone—Malaise—Doxorubicin—hematologic cancer	7.69e-05	0.000179	CcSEcCtD
Lubiprostone—Rash—Triamcinolone—hematologic cancer	7.68e-05	0.000178	CcSEcCtD
Lubiprostone—Dry mouth—Epirubicin—hematologic cancer	7.68e-05	0.000178	CcSEcCtD
Lubiprostone—Dermatitis—Triamcinolone—hematologic cancer	7.67e-05	0.000178	CcSEcCtD
Lubiprostone—Anorexia—Methotrexate—hematologic cancer	7.66e-05	0.000178	CcSEcCtD
Lubiprostone—Syncope—Doxorubicin—hematologic cancer	7.65e-05	0.000178	CcSEcCtD
Lubiprostone—Headache—Triamcinolone—hematologic cancer	7.63e-05	0.000177	CcSEcCtD
Lubiprostone—Abdominal pain—Prednisone—hematologic cancer	7.6e-05	0.000177	CcSEcCtD
Lubiprostone—CBR1—Metabolism—MTHFR—hematologic cancer	7.59e-05	0.00113	CbGpPWpGaD
Lubiprostone—Diarrhoea—Dexamethasone—hematologic cancer	7.56e-05	0.000176	CcSEcCtD
Lubiprostone—Diarrhoea—Betamethasone—hematologic cancer	7.56e-05	0.000176	CcSEcCtD
Lubiprostone—Palpitations—Doxorubicin—hematologic cancer	7.54e-05	0.000175	CcSEcCtD
Lubiprostone—Oedema—Epirubicin—hematologic cancer	7.52e-05	0.000175	CcSEcCtD
Lubiprostone—Loss of consciousness—Doxorubicin—hematologic cancer	7.5e-05	0.000174	CcSEcCtD
Lubiprostone—Cough—Doxorubicin—hematologic cancer	7.44e-05	0.000173	CcSEcCtD
Lubiprostone—Shock—Epirubicin—hematologic cancer	7.4e-05	0.000172	CcSEcCtD
Lubiprostone—Nervous system disorder—Epirubicin—hematologic cancer	7.38e-05	0.000171	CcSEcCtD
Lubiprostone—Tachycardia—Epirubicin—hematologic cancer	7.34e-05	0.000171	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Methotrexate—hematologic cancer	7.32e-05	0.00017	CcSEcCtD
Lubiprostone—Skin disorder—Epirubicin—hematologic cancer	7.31e-05	0.00017	CcSEcCtD
Lubiprostone—Dizziness—Betamethasone—hematologic cancer	7.3e-05	0.00017	CcSEcCtD
Lubiprostone—Dizziness—Dexamethasone—hematologic cancer	7.3e-05	0.00017	CcSEcCtD
Lubiprostone—Hyperhidrosis—Epirubicin—hematologic cancer	7.27e-05	0.000169	CcSEcCtD
Lubiprostone—Chest pain—Doxorubicin—hematologic cancer	7.26e-05	0.000169	CcSEcCtD
Lubiprostone—Myalgia—Doxorubicin—hematologic cancer	7.26e-05	0.000169	CcSEcCtD
Lubiprostone—Anxiety—Doxorubicin—hematologic cancer	7.24e-05	0.000168	CcSEcCtD
Lubiprostone—Nausea—Triamcinolone—hematologic cancer	7.23e-05	0.000168	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	7.21e-05	0.000168	CcSEcCtD
Lubiprostone—Discomfort—Doxorubicin—hematologic cancer	7.17e-05	0.000167	CcSEcCtD
Lubiprostone—Anorexia—Epirubicin—hematologic cancer	7.17e-05	0.000167	CcSEcCtD
Lubiprostone—Dyspnoea—Methotrexate—hematologic cancer	7.17e-05	0.000167	CcSEcCtD
Lubiprostone—Dry mouth—Doxorubicin—hematologic cancer	7.1e-05	0.000165	CcSEcCtD
Lubiprostone—Hypersensitivity—Prednisone—hematologic cancer	7.09e-05	0.000165	CcSEcCtD
Lubiprostone—Dyspepsia—Methotrexate—hematologic cancer	7.08e-05	0.000164	CcSEcCtD
Lubiprostone—Vomiting—Betamethasone—hematologic cancer	7.02e-05	0.000163	CcSEcCtD
Lubiprostone—Vomiting—Dexamethasone—hematologic cancer	7.02e-05	0.000163	CcSEcCtD
Lubiprostone—Decreased appetite—Methotrexate—hematologic cancer	6.99e-05	0.000162	CcSEcCtD
Lubiprostone—Rash—Betamethasone—hematologic cancer	6.96e-05	0.000162	CcSEcCtD
Lubiprostone—Rash—Dexamethasone—hematologic cancer	6.96e-05	0.000162	CcSEcCtD
Lubiprostone—Oedema—Doxorubicin—hematologic cancer	6.96e-05	0.000162	CcSEcCtD
Lubiprostone—Dermatitis—Betamethasone—hematologic cancer	6.96e-05	0.000162	CcSEcCtD
Lubiprostone—Dermatitis—Dexamethasone—hematologic cancer	6.96e-05	0.000162	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Methotrexate—hematologic cancer	6.94e-05	0.000161	CcSEcCtD
Lubiprostone—Fatigue—Methotrexate—hematologic cancer	6.93e-05	0.000161	CcSEcCtD
Lubiprostone—Headache—Dexamethasone—hematologic cancer	6.92e-05	0.000161	CcSEcCtD
Lubiprostone—Headache—Betamethasone—hematologic cancer	6.92e-05	0.000161	CcSEcCtD
Lubiprostone—Asthenia—Prednisone—hematologic cancer	6.9e-05	0.00016	CcSEcCtD
Lubiprostone—Pain—Methotrexate—hematologic cancer	6.87e-05	0.00016	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Epirubicin—hematologic cancer	6.85e-05	0.000159	CcSEcCtD
Lubiprostone—Shock—Doxorubicin—hematologic cancer	6.85e-05	0.000159	CcSEcCtD
Lubiprostone—Nervous system disorder—Doxorubicin—hematologic cancer	6.83e-05	0.000159	CcSEcCtD
Lubiprostone—Tachycardia—Doxorubicin—hematologic cancer	6.79e-05	0.000158	CcSEcCtD
Lubiprostone—Skin disorder—Doxorubicin—hematologic cancer	6.76e-05	0.000157	CcSEcCtD
Lubiprostone—Hyperhidrosis—Doxorubicin—hematologic cancer	6.73e-05	0.000156	CcSEcCtD
Lubiprostone—Dyspnoea—Epirubicin—hematologic cancer	6.71e-05	0.000156	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	6.69e-05	0.000997	CbGpPWpGaD
Lubiprostone—Anorexia—Doxorubicin—hematologic cancer	6.64e-05	0.000154	CcSEcCtD
Lubiprostone—Feeling abnormal—Methotrexate—hematologic cancer	6.62e-05	0.000154	CcSEcCtD
Lubiprostone—Dyspepsia—Epirubicin—hematologic cancer	6.62e-05	0.000154	CcSEcCtD
Lubiprostone—Diarrhoea—Prednisone—hematologic cancer	6.58e-05	0.000153	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Methotrexate—hematologic cancer	6.57e-05	0.000153	CcSEcCtD
Lubiprostone—Nausea—Dexamethasone—hematologic cancer	6.56e-05	0.000152	CcSEcCtD
Lubiprostone—Nausea—Betamethasone—hematologic cancer	6.56e-05	0.000152	CcSEcCtD
Lubiprostone—Decreased appetite—Epirubicin—hematologic cancer	6.54e-05	0.000152	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Epirubicin—hematologic cancer	6.5e-05	0.000151	CcSEcCtD
Lubiprostone—Fatigue—Epirubicin—hematologic cancer	6.49e-05	0.000151	CcSEcCtD
Lubiprostone—Pain—Epirubicin—hematologic cancer	6.43e-05	0.000149	CcSEcCtD
Lubiprostone—Constipation—Epirubicin—hematologic cancer	6.43e-05	0.000149	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PIK3CG—hematologic cancer	6.38e-05	0.000951	CbGpPWpGaD
Lubiprostone—Dizziness—Prednisone—hematologic cancer	6.36e-05	0.000148	CcSEcCtD
Lubiprostone—Abdominal pain—Methotrexate—hematologic cancer	6.36e-05	0.000148	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	6.34e-05	0.000147	CcSEcCtD
Lubiprostone—Dyspnoea—Doxorubicin—hematologic cancer	6.21e-05	0.000144	CcSEcCtD
Lubiprostone—Feeling abnormal—Epirubicin—hematologic cancer	6.2e-05	0.000144	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Epirubicin—hematologic cancer	6.15e-05	0.000143	CcSEcCtD
Lubiprostone—Dyspepsia—Doxorubicin—hematologic cancer	6.13e-05	0.000142	CcSEcCtD
Lubiprostone—Vomiting—Prednisone—hematologic cancer	6.12e-05	0.000142	CcSEcCtD
Lubiprostone—Rash—Prednisone—hematologic cancer	6.07e-05	0.000141	CcSEcCtD
Lubiprostone—Dermatitis—Prednisone—hematologic cancer	6.06e-05	0.000141	CcSEcCtD
Lubiprostone—Decreased appetite—Doxorubicin—hematologic cancer	6.05e-05	0.000141	CcSEcCtD
Lubiprostone—Headache—Prednisone—hematologic cancer	6.03e-05	0.00014	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Doxorubicin—hematologic cancer	6.01e-05	0.00014	CcSEcCtD
Lubiprostone—Fatigue—Doxorubicin—hematologic cancer	6e-05	0.000139	CcSEcCtD
Lubiprostone—Constipation—Doxorubicin—hematologic cancer	5.95e-05	0.000138	CcSEcCtD
Lubiprostone—Pain—Doxorubicin—hematologic cancer	5.95e-05	0.000138	CcSEcCtD
Lubiprostone—Abdominal pain—Epirubicin—hematologic cancer	5.95e-05	0.000138	CcSEcCtD
Lubiprostone—Hypersensitivity—Methotrexate—hematologic cancer	5.92e-05	0.000138	CcSEcCtD
Lubiprostone—CBR1—Metabolism—CREBBP—hematologic cancer	5.91e-05	0.000881	CbGpPWpGaD
Lubiprostone—Asthenia—Methotrexate—hematologic cancer	5.77e-05	0.000134	CcSEcCtD
Lubiprostone—Feeling abnormal—Doxorubicin—hematologic cancer	5.74e-05	0.000133	CcSEcCtD
Lubiprostone—Nausea—Prednisone—hematologic cancer	5.71e-05	0.000133	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Doxorubicin—hematologic cancer	5.69e-05	0.000132	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PIK3CD—hematologic cancer	5.61e-05	0.000836	CbGpPWpGaD
Lubiprostone—Hypersensitivity—Epirubicin—hematologic cancer	5.54e-05	0.000129	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ALB—hematologic cancer	5.53e-05	0.000825	CbGpPWpGaD
Lubiprostone—Abdominal pain—Doxorubicin—hematologic cancer	5.5e-05	0.000128	CcSEcCtD
Lubiprostone—Diarrhoea—Methotrexate—hematologic cancer	5.5e-05	0.000128	CcSEcCtD
Lubiprostone—Asthenia—Epirubicin—hematologic cancer	5.4e-05	0.000125	CcSEcCtD
Lubiprostone—Dizziness—Methotrexate—hematologic cancer	5.32e-05	0.000124	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PIK3R1—hematologic cancer	5.29e-05	0.000789	CbGpPWpGaD
Lubiprostone—Diarrhoea—Epirubicin—hematologic cancer	5.15e-05	0.00012	CcSEcCtD
Lubiprostone—Hypersensitivity—Doxorubicin—hematologic cancer	5.13e-05	0.000119	CcSEcCtD
Lubiprostone—Vomiting—Methotrexate—hematologic cancer	5.11e-05	0.000119	CcSEcCtD
Lubiprostone—Rash—Methotrexate—hematologic cancer	5.07e-05	0.000118	CcSEcCtD
Lubiprostone—Dermatitis—Methotrexate—hematologic cancer	5.06e-05	0.000118	CcSEcCtD
Lubiprostone—Headache—Methotrexate—hematologic cancer	5.04e-05	0.000117	CcSEcCtD
Lubiprostone—Asthenia—Doxorubicin—hematologic cancer	4.99e-05	0.000116	CcSEcCtD
Lubiprostone—Dizziness—Epirubicin—hematologic cancer	4.98e-05	0.000116	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PIK3CB—hematologic cancer	4.89e-05	0.000728	CbGpPWpGaD
Lubiprostone—Vomiting—Epirubicin—hematologic cancer	4.78e-05	0.000111	CcSEcCtD
Lubiprostone—Nausea—Methotrexate—hematologic cancer	4.78e-05	0.000111	CcSEcCtD
Lubiprostone—Diarrhoea—Doxorubicin—hematologic cancer	4.76e-05	0.000111	CcSEcCtD
Lubiprostone—Rash—Epirubicin—hematologic cancer	4.74e-05	0.00011	CcSEcCtD
Lubiprostone—Dermatitis—Epirubicin—hematologic cancer	4.74e-05	0.00011	CcSEcCtD
Lubiprostone—Headache—Epirubicin—hematologic cancer	4.71e-05	0.00011	CcSEcCtD
Lubiprostone—Dizziness—Doxorubicin—hematologic cancer	4.6e-05	0.000107	CcSEcCtD
Lubiprostone—Nausea—Epirubicin—hematologic cancer	4.47e-05	0.000104	CcSEcCtD
Lubiprostone—Vomiting—Doxorubicin—hematologic cancer	4.43e-05	0.000103	CcSEcCtD
Lubiprostone—Rash—Doxorubicin—hematologic cancer	4.39e-05	0.000102	CcSEcCtD
Lubiprostone—Dermatitis—Doxorubicin—hematologic cancer	4.39e-05	0.000102	CcSEcCtD
Lubiprostone—Headache—Doxorubicin—hematologic cancer	4.36e-05	0.000101	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PTEN—hematologic cancer	4.22e-05	0.000629	CbGpPWpGaD
Lubiprostone—Nausea—Doxorubicin—hematologic cancer	4.13e-05	9.61e-05	CcSEcCtD
Lubiprostone—CBR1—Metabolism—EP300—hematologic cancer	4.03e-05	0.0006	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CA—hematologic cancer	2.98e-05	0.000444	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—AKT1—hematologic cancer	2.43e-05	0.000363	CbGpPWpGaD
